How Mark Cuban is Turning the Prescription Drug Industry Upside Down

When Mark Cuban enters an industry, he typically disrupts it in one way or another. And that’s precisely what it appears he has done once again, though this time in the healthcare space. His Cost Plus Drug Company has turned the industry on its head and introduced transparency to the previously opaque area of prescription drug prices.

“We started [Mark Cuban Cost Plus Drug Company] with the goal of being the low-cost provider for generic drugs,” Cuban told MarketScale. 

The company’s website features a chart displaying the stark difference in the retail price of these drugs versus what consumers pay through their platform. But perhaps the most striking thing about the Cost Plus Drug Company is the clarity of the pricing structure. Leadership has been vocal, on the site and on social media, about how Cost Plus Drugs gets to its final prices in an effort to set a new standard for patient-focused transparency.

For example, every drug is priced with the same markups: a 15% markup supports operations, a $3 charge covers pharmacy labor, and then the usual fixed and variable costs of shipping round out the total. Some savings are minimal; a 60-count of 20mg Fluoxetine, the generic alternative for depression and OCD treatment drug Prozac, costs $4.80 for a Cost Plus Drugs customer, compared to the retail price of $43.80.

Some savings are so stark that they warrant a double take. For a 30-count of 400mg Imatinib, the generic version of leukemia-treatment drug Gleevec, Cost Plus Drugs customers pay $47.50, compared to the retail price of $9,657.40, an enormous difference in cost.

“We will do whatever it takes to get affordable pharmaceuticals to patients,” said Alex Oshmyansky, CEO of Mark Cuban Cost Plus Drug. “The markup on potentially lifesaving drugs that people depend on is a problem that can’t be ignored. It is imperative that we take action and help expand access to these medications for those who need them most.”

With this cost savings business model, underinsured or uninsured patients who’d be paying close to or full price would see the most immediate benefits. Even insured patients though, according to the company’s site, would pay “less than what you would pay when using your insurance at a typical pharmacy.”

The cost of drugs in the United States has been a problem for some time, garnering attention from President Biden and putting a financial strain on many Americans. According to Kevin Stevenson, Director of Strategic Operations at Providence Healthcare Network in Waco, TX, affecting positive change in this side of the industry is critical, as for patients, it’s truly a life or death situation.

“People who don’t have insurance that are paying out of pocket, oftentimes they skip medications because they take food out of their family’s mouth,” Stevenson said.

The high-profile attention that Cuban’s company, as well as the issue at-large, is getting could be a sign of things to come for healthcare in the United States.

“I think we’re seeing people in healthcare now that are having that more entrepreneurial mindset, that are looking at problems and saying how can we look at it from a different viewpoint to try to solve this,” he said.

Stevenson admitted that change in healthcare can come slowly, but with sharks like Mark Cuban in the water, change could be coming sooner rather than later. 

Follow us on social media for the latest updates in B2B!

Image

Latest

student visibility
Why Student Visibility Matters in Today’s Schools
March 3, 2026

School Safety Today podcast, presented by Raptor Technologies. In this episode of School Safety Today by Raptor Technologies, host Dr. Amy Grosso interviews SRO Todd Brendel of Dayton Independent Schools (KY), who shares frontline insights on the importance of knowing where students and staff are throughout the school day. He explains how they manage…

Read More
skilled trades mentorship
Why the Trades Need a Cultural Reset to Attract and Retain the Next Generation
March 3, 2026

The skilled trades are at a critical crossroads. According to an August 2025 report from the Institute for Women’s Policy Research (IWPR), the number of women working in construction and extraction occupations rose to 366,360 in 2024, the highest level ever recorded. Yet despite that growth, women still account for only about 4.3% of construction…

Read More
virtual physical therapy
Virtual Physical Therapy and the Changing Landscape of Athlete Care
March 3, 2026

Virtual care is no longer an experiment—it’s a structural shift in healthcare. Telehealth usage remains significantly higher than pre-2020 levels, and providers across disciplines are rethinking how to deliver higher-quality outcomes without the overhead and insurance constraints of traditional clinics. Meanwhile, recreational and endurance sports participation continues to rise, with millions of Americans registering…

Read More
employer
Why Institution-Wide Employer Alignment Will Define the Next Era of Higher Ed
March 2, 2026

Higher education is at an inflection point. Institutions are facing a demographic cliff in traditional-age enrollment, softening international pipelines, and increasing scrutiny around the return on investment of a degree. At the same time, the World Economic Forum reports that 59 out of every 100 workers globally are projected to require reskilling or upskilling…

Read More